Etiopathogenesis, diagnosis and treatment – an update

The pathogenesis of hidradenitis suppurativa (HS) has not yet been fully clarified; it is assumed that there are multifactorial interactions. The most important risk factors and comorbidities include smoking, obesity and metabolic syndrome. A multimodal treatment approach is generally recommended. In addition to non-drug measures and topical preparations, system therapies, surgical interventions and other therapeutic modalities are also used depending on the severity. In addition to adalimumab, secukinumab has also been available as a biologic in Switzerland since 2023.